Amylyx Pharmaceuticals Inc (AMLX) - Total Liabilities
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has total liabilities worth $27.39 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Amylyx Pharmaceuticals Inc to assess how effectively this company generates cash.
Amylyx Pharmaceuticals Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check AMLX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Amylyx Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
A10 Network
NYSE:ATEN
|
USA | $418.27 Million |
|
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
|
China | CN¥1.56 Billion |
|
Veris Residential Inc
NYSE:VRE
|
USA | $1.51 Billion |
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
China | CN¥7.50 Billion |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
China | CN¥6.09 Billion |
|
JetBlue Airways Corp
NASDAQ:JBLU
|
USA | $14.33 Billion |
|
Avi Ltd
JSE:AVI
|
South Africa | ZAC5.15 Billion |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
Korea | ₩2.53 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Amylyx Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AMLX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amylyx Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Amylyx Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $27.39 Million | -5.14% |
| 2024-12-31 | $28.87 Million | -65.64% |
| 2023-12-31 | $84.02 Million | +65.25% |
| 2022-12-31 | $50.85 Million | -80.20% |
| 2021-12-31 | $256.78 Million | +217.69% |
| 2020-12-31 | $80.83 Million | +182.85% |
| 2019-12-31 | $28.58 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more